Simvastatin enhances proliferation and pluripotent gene expression by canine bone marrow-derived mesenchymal stem cells (cBM-MSCs) in vitro

Sirirat Nantavisai a,b,1, Watchareewan Rodprasert a,b,1, Koranis Pathanachaia b,d, Parattakorn Wikran c, Podchana Kitcharoenthaworn c, Saritpakorn Smithiwong c, Suyakarn Archasappawat c, Chenphop Sawangmake a,b,d,*

a Veterinary Pharmacology and Stem Cell Research Laboratory, Veterinary Stem Cell and Bioengineering Innovation Center (VSCBIC), Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330, Thailand
b Special Task Force for Activating Research (STAR) in Biology of Embryo and Stem Cell Research in Veterinary Science, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330, Thailand
c Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330, Thailand
d Department of Pharmacology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330, Thailand

ARTICLE INFO

Keywords:
Cell biology
Cell culture
Cell death
Cytotoxicity
Stem cell research
Regenerative medicine
Canine bone marrow-derived mesenchymal stem cells (cBM-MSCs)
Simvastatin
Proliferation
Stemness genes

ABSTRACT

Establishing the intervention to enhance proliferation and differentiation potential is crucial for the clinical translation of stem cell-based therapy. In this study, the effects of simvastatin on these regards were explored. Canine bone marrow-derived mesenchymal stem cells (cBM-MSCs) were treated with 4 doses of simvastatin, 0.1, 1, 10, and 100 nM. Simvastatin in low-dose range, 0.1 and 1 nM, enhanced dose-dependent cell proliferation at day 5 and 7. Exploration of the mechanisms revealed that simvastatin in low-dose range dose-dependently upregulated sets of cell cycle regulators, Cyclin D1 and Cyclin D2; proliferation marker, Ki-67; and anti-apoptotic gene; Bcl-2. Interestingly, pluripotent markers, Rex1 and Oct4, were dramatically increased upon the low-dose treatment. Contrastingly, treatment with high-dose simvastatin suppressed the expression of those genes. Thus, the results suggested beneficial effects of simvastatin on cBM-MSCs proliferation and expansion. Further study regarding differentiation potential and underlying mechanisms will accelerate the clinical application of the molecule on veterinary stem cell-based therapy.

1. Introduction

Mesenchymal stem cells (MSCs) have been isolated from various types of tissues. Among them, MSCs isolated from bone marrow (BM), so-called bone marrow-derived MSCs (BM-MSCs), contained a distinguished potential for regenerative treatment due to their availability, multi-potentiality, immunomodulating ability, and homing capability (Schafer et al., 2016). Isolation of canine BM-MSCs (cBM-MSCs) has been reported previously by using different isolation and expansion techniques (Sawangmake et al., 2019; Ippokratis et al., 2007; Kadiyala et al., 1997). The most sites for BM collection were ilium and femur (Catana et al., 2008; Eca et al., 2009). The collected BM was then processed for MSCs isolation using various cell isolation techniques i.e. physiological-buffered solution washing, red blood cell (RBC) lysis, and gradient centrifugation (Juopperi et al., 2007). The normalized isolated MSCs number per tissue mass of cBM-MSCs was higher than other MSCs resources e.g. adipose tissue and synovial fluid (Giai Via, Frizziero and Oliva, 2012; Liao and Chen, 2014). However, the expansion rate of the cells was lower than canine adipose-derived MSCs (cAD-MSCs). The lowered cell proliferation and altered cell morphology were found in higher cell passage (Lennon et al., 2012). These suggested the burdens in cBM-MSCs expansion during the process of cell amplification.

Besides, the multipotentiality of cBM-MSCs has been illustrated by the in vitro induction toward osteogenic, chondrogenic, and adipogenic lineages (Ciuffreda et al., 2016; Csaki et al., 2007). These evidences suggested the plasticity of cells and the potential application for stem-cell based regenerative treatment. However, comparing with embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), the differentiation potential of MSCs was much lower (Zomer et al., 2015). This burden led to the gap for introducing MSCs toward clinical application. Many MSCs...
strategies have been studied and proposed for improving MSCs plasticity and proliferative capability.

Simvastatin, a statin cholesterol-lowering drug, has been proposed as a potential enhancing molecule for MSCs culture. In addition to the effect as a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, it has been illustrated that the drug contained beneficial pleiotropic effects on cell proliferation and differentiation in vitro (Pagkalos et al., 2010; Qiao et al., 2011). Previous publications reported the promoting effect of simvastatin on the osteogenic differentiation potential of BM-MSCs as illustrated by an increased osteogenic marker expression (Pagkalos et al., 2010; Tai et al., 2015). Positive effect of simvastatin on proliferation has been reported as a dose-dependent enhanced periodontal ligament (PDL) cells proliferation assessed by BrdU assay (Yazawa et al., 2005). Toxicity testing of dose-dependent enhanced periodontal ligament (PDL) cells proliferation assessed by BrdU assay (Yazawa et al., 2005).

The evidence suggested the potential application of simvastatin along with the importance of dose adjustment on cBM-MSCs culture aiming for enhancing the proliferation and differentiation capabilities.

Thus, this study was aimed for exploring the effect and optimizing the simvastatin dose on cBM-MSCs proliferation and pluripotent marker expression along with the exploration of related mechanisms.

2. Materials and methods

2.1. Bone marrow collection

The protocol was approved by the Institutional Animal Care and Use Committee (IACUC), the Faculty of Veterinary Science, Chulalongkorn University. Bone marrow (BM) was collected from the healthy canine donors with the owners’ consents. BM was collected from ilium or femur (Kraus and Kirker-Head, 2006). Aseptic technique was employed throughout the procedures. BM aspiration was performed by using 18-gauge Jamshidi® bone marrow biopsy needles (BD, USA) assembled with 10 mL syringe containing heparin solution (2,500 IU heparin/1 mL bone marrow aspirate). The volume of the aspirated bone marrow was not exceeded 1 mL/kg body weight. The collected BM was kept in sterile bag, placed on ice, and immediately transported to the laboratory.

2.2. cBM-MSCs isolation, culture, and expansion

For cBM-MSCs isolation, the aspirated bone marrow was mixed with 10 mL Hank’s Balanced Salt Solution (HBSS) (Thermo Fisher Scientific Corporation, USA) as a washing solution. After centrifugation at 300 rpm for 15 min, the supernatant, solution above the white ring layer lied over red blood cell, was gently discarded. The second wash with 20 mL HBSS was performed at 1,000 rpm for 15 min, and the aspirant was gently discarded. The pellet was gently resuspended with 10 mL Gibco™ Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) (Thermo Fisher Scientific Corporation, USA) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific Corporation, USA), 2 mM L-glutamine, and 1% Antibiotic-Antimycotic solution (Thermo Fisher Scientific Corporation, USA). Cells were seeded in T-75 Corning® treated tissue culture flasks (Corning, USA) containing pre-warmed culture medium and subsequently incubated under 5% CO2 and 95% air at 37°C condition. The culture medium, 10% FBS-DMEM/F12, was replaced every 48 h. Cells were subcultured once the confluence reached 80% using 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) (Thermo Fisher Scientific Corporation, USA). Cells in passage 2–5 were used for the experiments.

2.3. Proliferation assay

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the cell proliferation at day 1, 5, and 7. To explore the proliferative effects of simvastatin, cells were starved with serum free (SF)-DMEM/F12 for 3 h and then maintained in 2% FBS-DMEM/F12 supplemented with 4 simvastatin doses (0.1, 1, 10, and 100 nM). The medium was routinely changed every 48 h. At day 1, 5, and 7 post-treatment, MTT assay was performed according to the following protocol. Briefly, cells were gently washed with 500 μL pre-warmed phosphate buffer saline (PBS) solution per well, and then incubated with 300 μL 0.5 mg/mL MTT solution under 5% CO2 and 95% air at 37°C condition for 15 min. After discarding the MTT solution, 1 mL of glycine buffered-dimethylsulfoxide (DMSO) solution was added for elution. The optical density was measured at 570 nm wavelength (Riss et al., 2013). The data were presented as a relative proliferation normalized with untreated control group.

2.4. Gene expression analysis

For the analysis of gene expression profiles, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used. At 48 h post-treatment, the mRNA expressions of simvastatin-treated cells were analyzed according the following protocols. Briefly, total RNA was harvested by using TRIzol-RNA isolation reagent (Thermo Fisher Scientific Corporation, USA) and DirectZol-RNA isolation kit (ZymoResearch, USA) according to manufacturer’s protocols. The obtained RNA products were converted to complementary DNA (cDNA) by using reverse transcriptase enzyme kit (Promega, USA). The relative mRNA expressions were normalized with reference gene, Glyceraldehyde 3-phosphate dehydrogenase (Gapdh), and with untreated control according to the following formula: \( \frac{(Ct_{target\ gene} - Ct_{Gapdh})_{treated} - (Ct_{target\ gene} - Ct_{Gapdh})_{control}}{Ct_{Gapdh}} \) where \( \Delta\Delta C_t \) referred to cycle threshold. The amplification primers were summarized in Table 1.

2.5. Fluorescence staining

To illustrate the occurrence of apoptotic and necrotic cells, live/dead (NUCLAER-ID® Blue/Red cell viability) (Enzo Life Sciences, USA) and Annexin V-FITC/propidium iodide (PI) (BD Biosciences, USA) staining was performed according to previous report and manufacturer’s protocol (Gelzo et al., 2014). The results were observed under a fluorescent microscope incorporated with Carl ZeissTM Apotome.2 apparatus (Carl Zeiss, Germany).

2.6. Statistical analysis

Data was expressed as mean ± standard deviation (SD). For comparison of data among groups, analysis of variance (ANOVA) was used, and Dunnet’s test was performed as post hoc analysis. Statistical significance was recognized when p-value < 0.05.

3. Results

3.1. cBM-MSCs culture and expansion

cBM-MSCs could be isolated, cultured, and expanded in vitro. Morphology of the isolated cells were fibroblast-like structure (Fig. 1). Expression of pluripotent markers, Rex1 and Oct4, was routinely analyzed in every isolation batch using RT-qPCR (data not shown).

3.2. cBM-MSCs proliferation property

Effect of simvastatin (0.1, 1, 10, and 100 nM) on cBM-MSCs
proliferation was explored. The relative proliferation at day 1, 5, and 7 was plotted (Fig. 2). The significant beneficial effect of simvastatin on proliferation was found at day 5 and 7. At day 7, 1 nM simvastatin showed the highest proliferative effect compared to other doses. Cell morphology of the treated cells were explored in order to investigate the cytotoxicity of the treatment. Cell morphology upon treatment at day 1 and 5 was normal (Fig. 3).

Table 1

| Gene                                     | Accession number | Sequences 5'→3' | Length (bp) | Tm (°C) |
|------------------------------------------|------------------|-----------------|-------------|---------|
| Zinc finger protein 42 (ZFP42 or Rex1)   | XM_022425491.1   | Forward         | 199         | 59.24   |
|                                          |                  | Reverse         |             | 60.73   |
| Octamer-binding transcription factor 4 (Oct4) | XM_538830.3     | Forward         | 100         | 60.55   |
|                                          |                  | Reverse         |             | 60.74   |
| G1/S-specific cyclin-D1 (Cyclin-D1)      | NM_001005757.1   | Forward         | 137         | 59.50   |
|                                          |                  | Reverse         |             | 59.50   |
| G1/S-specific cyclin-D2 (Cyclin-D2)      | XM_849493.5      | Forward         | 147         | 74.80   |
|                                          |                  | Reverse         |             | 74.40   |
| Proliferation marker protein Ki-67 (Ki67)| XM_022411692.1   | Forward         | 124         | 58.49   |
|                                          |                  | Reverse         |             | 58.49   |
| Tumor protein p53 (TP53)                 | NM_001003210.1   | Forward         | 109         | 75.30   |
|                                          |                  | Reverse         |             | 74.60   |
| B-cell lymphoma2 (Bcl-2)                 | NM_001002949.1   | Forward         | 100         | 65.00   |
|                                          |                  | Reverse         |             | 65.80   |
| BCL2 like 1 (BCL-2-L1)                   | NM_001003072.1   | Forward         | 77          | 65.60   |
|                                          |                  | Reverse         |             | 65.40   |
| Caspase 3 (CASP3)                        | NM_001003042.1   | Forward         | 79          | 76.40   |
|                                          |                  | Reverse         |             | 76.60   |
| Caspase 8 (CASP8)                        | NM_001048029.1   | Forward         | 70          | 76.40   |
|                                          |                  | Reverse         |             | 76.60   |
| Caspase 9 (CASP9)                        | NM_001031633.1   | Forward         | 97          | 76.40   |
|                                          |                  | Reverse         |             | 76.60   |
| Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) | NM_001003142.1 | Forward         | 100         | 59.38   |
|                                          |                  | Reverse         |             | 59.67   |

Fig. 1. Morphology of canine bone marrow-derived mesenchymal stem cells (cBM-MSCs). Morphology of the isolated cBM-MSCs was observed under phase-contrast microscope. Magnifications were 40X (A) and 100X (B), respectively.

Fig. 2. Relative proliferation of cBM-MSCs upon simvastatin treatment. Proliferative effect of simvastatin was tested. Four simvastatin doses (0.1, 1, 10, and 100 nM) were used, and the MTT assay was explored at day 1, 5, and 7 after treatment. The results were normalized with untreated control group in each day and illustrated as relative cell proliferation. The asterisks indicate statistical difference compared with the control (p-value < 0.05).
3.3. Simvastatin enhances cBM-MSCs pluripotent gene expression

To assess the effect of simvastatin on stemness property of cBM-MSCs. Expression of pivotal pluripotent gene markers, Rex1 and Oct4, were evaluated using RT-qPCR (Fig. 4). After 48 h post-treatment, simvastatin (0.1, 1, and 100 nM) could enhance the expression of Rex1 significantly. For Oct4 expression, only 1 nM simvastatin could enhance the significant upregulation. Interestingly, 1 nM simvastatin exerted dramatic effects on the upregulation of both markers.

3.4. Simvastatin promotes cBM-MSCs cell cycle and exerts anti-apoptotic gene expression

To explore the related mechanisms of beneficial effects of simvastatin on cBM-MSCs proliferation, sets of gene that represent cell cycle regulation were analyzed at 48 h post-treatment. Simvastatin at 1 nM increased the level of Cyclin D1, while Simvastatin at 0.1 and 1 nM increased Cyclin D2 expression in cBM-MSCs. On the contrary, mRNA expressions of Cyclin D1 and Cyclin D2 were decreased in simvastatin-treated cBM-MSCs in high-dose, ranging from 10 nM to 100 nM. There was no significant effect of simvastatin on Ki-67 expression, while significant downregulation of TP53 was found in 10 nM treatment (Fig. 5).

For representative anti-apoptotic marker, low-dose simvastatin (0.1 and 1 nM) dose-dependently exerted Bcl-2 expression, while trend of suppression was found in simvastatin high-dose range (10 and 100 nM). There was no significant effect of simvastatin on Bcl-2-L1 and Caspase 3.

All dose range of simvastatin significantly suppressed Caspase 8 expression, while Caspase 9 was significantly suppressed in 100 nM treatment (Fig. 6).

Live/dead and Annexin V-FITC/PI staining was performed in order to distinguish the occurrence of cell early apoptosis or necrosis. The results illustrated that 0.1, 10, and 100 nM simvastatin treatment triggered an early apoptosis of some cell population, but there was no necrotic cell found in any group of treatment (Fig. 7A and B).

4. Discussion

Various strategies for enhancing the success of MSCs application have been proposed. Cell expansion and differentiation capacities have been included in the top priority since most of MSCs contain limited ability in these regards. For cell expansion issue, each MSCs require different in vitro culture condition due to their source of origin and cellular characteristics (Elahi et al., 2016). Most MSCs contain limited potential of differentiation comparing with ESCs and iPSCs (Diederichs and Tuan, 2014). Variety of culture media and supplements have been utilized in MSCs culture in order to enhance expansion and differentiation potential. However, the responses were varied in particular cell types suggesting the necessary for study in individual circumstance. Simvastatin also illustrated particular pleiotropic effects on various cell types e.g. osteogenic enhancement in pluripotent stem cells (Kavalipati et al., 2015). In this study, we illustrated that simvastatin could enhance proliferation capacity of cBM-MSCs. However, only 1 nM simvastatin could show an
Fig. 5. Effects of simvastatin on cBM-MSCs cell cycle-regulated gene expression in vitro. The effect of simvastatin (0.1, 1, 10, and 100 nM) on cBM-MSCs cell cycle-regulated gene expression was analyzed by using RT-qPCR. The mRNA expressions were analyzed at 48 h post-treatment. Cyclin D1, Cyclin D2, Ki-67, and TP53 were explored. mRNA expressions of the genes were presented as relative expression by normalizing with reference gene, Gapdh, and the control. The asterisks indicate statistical difference compared with the control (p-value < 0.05).

Fig. 6. Effects of simvastatin on cBM-MSCs apoptotic gene expression in vitro. The effect of simvastatin (0.1, 1, 10, and 100 nM) on cBM-MSCs apoptotic gene expression was analyzed by using RT-qPCR. The mRNA expressions were analyzed at 48 h post-treatment. Bcl-2, Bcl-2-L1, Caspase 3, Caspase 8, and Caspase 9 were explored. mRNA expressions of the genes were presented as relative expression by normalizing with reference gene, Gapdh, and the control. The asterisks indicate statistical difference compared with the control (p-value < 0.05).
obvious proliferative effect in vitro. These findings correlate with the previous reported by Zhao et al. that demonstrated the positive effects of simvastatin at 0.01 and 0.1 μM on the proliferation of periodontal ligament stem cells (PDLSCs) after 5-day treatment. In that report, simvastatin at 1 and 10 μM significantly suppressed the proliferation at day 3 and day 5 in comparison with the control (p < 0.01) (Zhao and Liu, 2014). In addition, 1 nM simvastatin also dramatically enhanced the expression of pluripotent markers, Rex1 and Oct4, suggesting the beneficial effects of the optimal dose simvastatin on cBM-MSCs proliferation and pluripotent marker expressions. In various molecular study, self-renewal marker like Rex1 (ZFN42) and Oct4 were of interest (Guercio et al., 2012; Kolf et al., 2007; Shi et al., 2006). These genes were recognized as the markers for undifferentiated ESCs and could indicate the pluripotent stage of cells (Kolf et al., 2007; Shi et al., 2006). MSCs from various mammalian species could express ESCs-related gene markers e.g. Rex1 and Oct4 (Kolf et al., 2007). The increase of these factors correlated with differentiation potential toward osteogenic and adipogenic lineages (Roche et al., 2007).

In the previous study revealed that human endothelial progenitor cells (EPCs) treated with atorvastatin, one of the HMG-CoA reductase inhibitors, modulated expression of cell cycle genes including up-regulation of cyclins (cyclin A and cyclin F) and downregulation of the cell cycle inhibitor (p27) corresponded with the result in this study (Assmus et al., 2003). Recent report suggested that high dose simvastatin ranging from (6.25 x 10^3 nM to 50 x 10^3 nM) could induce G1 arrest by down-regulating CyclinD1 and Cyclin E1 in human primary colorectal cancer cells, regardless of P53 status (Chen et al., 2018).

The additional exploration revealed an effect on anti-apoptotic gene, Bcl-2, upregulation. Bcl-2 family is apoptotic related genes controlling program cell death (Czabotar et al., 2014; Thomadaki and Scorilas, 2006) which consists of both anti-apoptotic and pro-apoptotic genes (Danial, 2007). The expressions of Bcl-2 family such as B cell lymphoma 2 (Bcl-2) which is anti-apoptotic gene marker was found to block the program rather than promote cell proliferation rate (Hardwick and Soane, 2013; Korsmeyer, 1999). Bcl-2 gene increased in low-dose of simvastatin, 0.1 and 1 nM, and corresponded with the result of Dong et al. report which
demonstrated that atorvastatin, one of the statin group, reduced apoptosis of porcine BM-MSCs and increased Bcl-2 gene (Dong et al., 2011).

All dose of simvastatin suppressed Caspase 8 expression, while Caspase 9 downregulation was found in 100 nM treatment. The initiator Caspases play a crucial role in triggering the executioner Caspases (Kim et al., 2015; Timmers and Green, 2017). It seemed that simvastatin downregulated the initiator of extrinsic pathway (Caspase 8), but only high dose simvastatin could suppress the intrinsic pathway initiator (Caspase 9) which might result in a proliferative effect of 100 nM treatment. In addition, according to the live/dead and Annexin V-FITC/PI staining, simvastatin (0.1, 10, and 100 nM) triggered early apoptosis of cells, but there was no necrotic cell found upon treatment. This might suggest the anti-apoptotic effect of a low-dose simvastatin treatment.

In conclusion, Simvastatin in low-dose (0.1 and 1 nM) illustrated in vitro proliferative effects on cBM-MSCs expansion by upregulating cell cycle regulators (Cyclin D1 and Cyclin D2), and anti-apoptotic gene (Bcl-2). Apoptotic initiators, especially Caspase 8, was also downregulated. Besides, the pluripotent markers, Rex1 and Oct4, were upregulated. Further study regarding molecular mechanisms and differentiation potential should be conducted in order to facilitate the clinical application of the molecule.

Declarations

Author contribution statement

S. Nantavisai, P. Wikran, P. Kitcharoenthaworn, S. Smithiwong and S. Archasappawat: Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

W. Rodprasert: Contributed reagents, materials, analysis tools or data; Wrote the paper.

K. Pathanachai: Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data. C. Sawangmake: Conceived and designed the experiments; Wrote the paper.

Funding statement

P. Wikran, P. Kitcharoenthaworn, S. Smithiwong, S. Archasappawat and C. Sawangmake were supported by the Senior Project Research Grant, Faculty of Veterinary Science, Chulalongkorn University. C. Sawangmake was supported by the Special Task Force for Activating Research (STAR) in Biology of Embryo and Stem Cell Research in Veterinary Science (#GSTAR 59-007-31-005), Ratchadaphiseksomphot Research (STAR) in Biology of Embryo and Stem Cell Research in Veterinary Science (#GSTAR 59-007-31-005), Ratchadaphiseksomphot Research Fund.

Additional information

No additional information is available for this paper.

References

Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., Walter, P., 2015. Molecular Biology of the Cell: the Cell Cycle, sixth ed. Garland Science, New York, NY.

Assmun, B., Urbich, C., Aicher, A., Hofmann, W.K., Haedeler, J., Rossig, L., Spyridopoulos, I., Zeiher, A.M., Dimmeler, S., 2003. HMGCoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 92 (5), 1049-1055.

Catana, L., Groza, I., Oana, L., Pâlî, E., Peștean, C., Catana, R., Cenariu, M., 2008. Canine mesenchymal stem cells isolation from bone marrow aspirates. Vet. Med. 65 (2), 1843-1878.

Chen, M.J., Cheng, A.C., Lee, M.F., Hu, Y.C., 2018. Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. J. Cell. Physiol. 233 (6), 4618-4625.

Dannian, W., Malpaso, C., Munoz, V.C., Giai Via, A., Frizziero, A., Oliva, F., 2012. Biological properties of mesenchymal Stem Cells from different sources: implications for tumor microenvironment. Stem Cell. Res. 5 (2), 103-127.

Devi, S., Tuan, R.S., 2014. Functional comparison of human-induced pluripotent stem cell-derived mesenchymal cells and bone marrow-derived mesenchymal stromal cells from the same donor. Stem Cells Dev. 23 (14), 1594-1610.

Dong, Q., Yang, Y., Song, L., Qian, H., Xu, Z., 2012. Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating AMP-activated protein kinase. Int. J. Cardiol. 153 (3), 311-316.

Eca, L.P., Ramalho, R.B., Oliveira, I.S., Gomes, P.O., Pontes, P., Ferreira, A.T., 2019. Comparative study of technique to obtain stem cells from bone marrow collection between the iliac crest and the femoral epiphysis in rabbits. Acta Cir. Bras. 24 (5), 400-404.

Elahi, K.C., Klein, G., Avci-Adali, M., Sievert, K.D., MacNeil, S., Aicher, W.K., 2016. Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. Stem Cell. Int. 2016, 5646384.

Gelzo, M., Granato, G., Alban, F., Arcucci, A., Russo, Dello A., De Vendittis, E., Ruocco, M.R., Corso, G., 2014. Evaluation of cytotoxic effects of 7-dehydrocholesterol on melanoma cells. Free Radic. Biol. Med. 70, 129-140.

Giai Via, A., Prizzi, A., Oliva, F., 2012. Biological properties of mesenchymal Stem Cells from different sources. Muscles Ligaments Tendons J. 2 (3), 154-162.

Guercio, A., Di Marco, P., Casella, S., Cannella, V., Russolito, L., Purpuri, G., Di Bella, S., Piccione, G., 2012. Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroarticular joints. Cell Biol. Int. 36 (2), 189-194.

Hardwick, J.M., Soane, L., 2013. Multiple functions of BCL-2 family proteins. Cold Spring Harb. Perspect. Biol. 5 (2).

Ippokratis, P., Diane, C., Paul, E., Giannoudis, V.P., 2007. Mesenchymal stem cell tissue engineering: techniques for isolation. Injury Int. J. Care Injured 38S4, 3-25.

Joopperi, T.A., Schuler, W., Yuan, X., Collector, M.I., Dang, C.V., Sharkis, S.J., 2007. Isolation of bone marrow-derived stem cells using density-gradient separation. Exp. Hematol. 35 (2), 335-341.

Kadiyla, S., Young, R.G., Thiede, M.A., Bruder, S.P., 1997. Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. Cell Transplant. 6 (2), 125-134.

Kavalipati, N., Shah, J., Ramakrishnan, A., Vasanwala, H., 2015. Pleiotropic effects of notch, inductive conditioning. Indian J. Endocrinol. Metab 19 (5), 554-562.

Kim, B., Srivastava, S.K., Kim, S.H., 2015. Caspase-9 as a therapeutic target for treating cancer. Expert Opin. Ther. Targets 19 (1), 113-127.

Koll, C.M., Cho, E., Tuan, R.S., 2007. Mesenchymal stromal cells. Biology of adult mesenchymal stem cell regulation of niche, self-renewal and differentiation. Arthritis Res. Ther. 9 (1), 204.

Korsmeyer, S.J., 1999. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59, 4625-4635.

Liao, H.T., Chen, C.T., 2014. Osteogenic potential: comparison between bone marrow and adipose-derived mesenchymal stem cells. World J. Stem Cells 6 (3), 288-295.

Pagkalos, J., Cha, J.M., Kang, Y., Heliotis, M., Tziridis, E., Manalarts, A., 2010. Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J. Bone Miner. Res. 25 (11), 2470-2478.

Qiao, L.J., Kang, K.L., Heo, J.S., 2011. Simvastatin promotes osteogenic differentiation of mouse embryonic stem cells via canonical Wnt/beta-catenin signaling. Mol. Cells 32 (5), 437-444.

Riss, T.L., Moravac, R.A., Niles, A.L., Benink, H.A., Worzella, T.J., Minor, L., 2013. Cell Viability Assays Activity Guide Manual.

Roche, S., Richard, M.J., Favrot, M.C., 2007. Oct-4, Rex-1, and Gata-4 expression in human mesenchymal stromal cells from different sources: implications for tumor microenvironment. Stem Cell. Int. 2016, 5646384.

Sawangmake, C., Nantavisai, S., Oathamnon, T., Pavanast, P., 2019. Osteogenic differentiation potential of canine bone marrow-derived mesenchymal stem cells under different beta-glucosamine phosphate concentrations in vitro. Thai J. Vet. Med. [Internet] 46 (4), 617–625, [cited 18 Oct. 2019]. Available from: https://www.tci-thaijo.org/index.php/tjvm/article/view/73793.

Scharfe, W., Spohn, G., Baer, V., 2016. Mesenchymal stem/stromal cells in regenerative medicine: can preconditioning strategies improve therapeutic efficacy? Transfus. Med. Hemotherapy 43 (4), 256-267.
Shi, W., Wang, H., Pan, G., Geng, Y., Guo, Y., Pei, D., 2006. Regulation of the pluripotency marker Rex-1 by Nanog and Sox2. J. Biol. Chem. 281 (33), 23319–23325.
Tai, I.C., Wang, V.H., Chen, C.H., Chuang, S.C., Chang, J.K., Ho, M.L., 2015. Simvastatin enhances Rho/actin/cell rigidity pathway contributing to mesenchymal stem cells' osteogenic differentiation. Int. J. Nanomed. 10, 5881–5894.
Thomadaki, H., Scorilas, A., 2006. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit. Rev. Clin. Lab. Sci. 43 (1), 1–67.
Tummers, B., Green, D.R., 2017. Caspase-8: regulating life and death. Immunol. Rev. 277 (1), 76–89.

Yazawa, H., Zimmermann, B., Asami, Y., Bernimoulin, J.-P., 2005. Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J. Periodontol. 76 (2), 295–302.
Zhao, B.J., Liu, Y.H., 2014. Simvastatin induces the osteogenic differentiation of human periodontal ligament stem cells. Fundam. Clin. Pharmacol. 28 (5), 583–592.
Zomer, H.D., Vidane, A.S., Goncalves, N.N., Ambrosio, C.E., 2015. Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives. Stem Cells Cloning 8, 125–134.